Your browser is old and is not supported. Upgrade for better security.

Adaptyv Biosystems

We use synthetic biology and nanofluidics for next-gen protein engineering

Last Funded March 2022


raised from 40 investors
Pitch Video
Investor Panel


In the future, all proteins will be made using cell-free synthetic biology
We are building the best platform to engineer proteins based on high-throughput nanofluidics
This way we generate the data needed for training ML models that can predict new protein designs
Our platform develops better therapies against targets in cancer, autoimmune & rare diseases

Our Team

Up till now, organisms were the workhorses of biotech and all proteins were made in cells. This decade, the industry will go cell-free and go beyond the proteins that are found in nature. With Adaptyv, we're enabling this next-gen protein engineering to create better therapeutics.

Slide deck